In vivo administration of purified human interleukin-2 to patients with cancer: Development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration

M. T. Lotze, M. C. Custer, S. O. Sharrow, L. A. Rubin, D. L. Nelson, S. A. Rosenberg

Research output: Contribution to journalArticle

Abstract

Recent studies have demonstrated efficacy of immunotherapies including interleukin-2 (IL-2) in the treatment of malignancies in rodents and humans. High levels of IL-2 receptor-positive cells were found in the peripheral blood of patients receiving recombinant IL-2 in these Phase I clinical trials. This was demonstrated both in patients receiving i.v. IL-2 who had detectable circulating levels of IL-2 as well as in patients receiving i.p. IL-2 who did not. Up to 100% of the anti-Tac binding could be inhibited by preincubation with IL-2 indicating that this was indeed an IL-2 receptor that was identified. Two-color experiments demonstrated that few Leu 2-positive cells (

Original languageEnglish (US)
Pages (from-to)2188-2195
Number of pages8
JournalCancer Research
Volume47
Issue number8
Publication statusPublished - 1987
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this